NCT00253903 - Efficacy and Safety of Eplivanserin Treatment for Sleep Maintenance Insomnia Followed by Optional Extension up to 1 Year | Biotech Hunter

Enrollment

1,155

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

November 30, 2007

Study Completion Date

September 30, 2008

Conditions

Sleep Initiation and Maintenance DisordersInsomnia

Interventions

DRUG

eplivanserin (SR46349)

oral administration

DRUG

placebo

oral administration

Trial Locations (14)

Sanofi-Aventis Administrative Office, Bridgewater

Sanofi-Aventis Administrative Office, Buenos Aires

Sanofi-Aventis Administrative Office, Macquarie Park

Sanofi-Aventis Administrative Office, Vienna

Sanofi-Aventis Administrative Office, Laval

Sanofi-Aventis Administrative Office, Santiago

Sanofi-Aventis Administrative Office, Prague

Sanofi-Aventis Administrative Office, Helsinki

Sanofi-Aventis Administrative Office, Paris

Sanofi-Aventis Administrative Office, Berlin

Sanofi-Aventis Administrative Office, México

Sanofi-Aventis Administrative Office, Gouda

Sanofi-Aventis Administrative Office, Barcelona

Sanofi-Aventis Administrative Office, Guildford